Home
CCCC
CCCC News

Latest C4 Therapeutics Inc. (CCCC) News on April 3, 2025

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

a month ago

UBS Adjusts C4 Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating

C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

a month ago

C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

Zacks

a month ago

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a month ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

a month ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

MT Newswires

2 months ago

UBS Downgrades C4 Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $18

3 Penny Stocks On US Exchanges To Consider In January 2025

Simply Wall St.

3 months ago

3 Penny Stocks On US Exchanges To Consider In January 2025

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

GlobeNewswire

3 months ago

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now

Zacks

3 months ago

Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now

Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?

Insider Monkey

3 months ago

Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?

MT Newswires

3 months ago

Wells Fargo Upgrades C4 Therapeutics to Overweight From Equalweight, Raises Price Target to $12 From $8

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

GlobeNewswire

4 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

GlobeNewswire

4 months ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

GlobeNewswire

5 months ago

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

5 months ago

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

5 months ago

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely

Simply Wall St.

5 months ago

We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

C4 Therapeutics Names Paige Mahaney as Chief Scientific Officer

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

GlobeNewswire

6 months ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

GlobeNewswire

6 months ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Evercore ISI Lifts Price Target on C4 Therapeutics to $10 From $9, Keeps Outperform Rating

MT Newswires

7 months ago

C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire

7 months ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

MT Newswires

7 months ago

C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

GlobeNewswire

7 months ago

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

MT Newswires

7 months ago

Top Premarket Decliners

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire

7 months ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

GlobeNewswire

7 months ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire

7 months ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

GlobeNewswire

8 months ago

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

C4 Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

C4 Therapeutics Second Quarter 2024 Earnings: Beats Expectations

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

8 months ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

Zacks

9 months ago

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

GlobeNewswire

9 months ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why

Zacks

9 months ago

C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

GlobeNewswire

9 months ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?

Insider Monkey

9 months ago

C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?

It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope

Simply Wall St.

10 months ago

It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope

MT Newswires

10 months ago

C4 Therapeutics Appoints Ron Cooper Board Chairman

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

GlobeNewswire

10 months ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Looking for a Fool-Proof Crypto Mining Experience? Trendsetting BlockDAG Network Just Launched its X1 Miner App and it’s a Game-Changer for “Smart-Mining”

GlobeNewswire

10 months ago

Looking for a Fool-Proof Crypto Mining Experience? Trendsetting BlockDAG Network Just Launched its X1 Miner App and it’s a Game-Changer for “Smart-Mining”

Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Altria Stock

Motley Fool

10 months ago

Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Altria Stock

Here's What Happens to Your Social Security When Your Spouse Passes Away

Motley Fool

10 months ago

Here's What Happens to Your Social Security When Your Spouse Passes Away

Is There Now An Opportunity In kneat.com, inc. (TSE:KSI)?

Simply Wall St.

10 months ago

Is There Now An Opportunity In kneat.com, inc. (TSE:KSI)?

PGA Tour reports 'progress' without details in meeting with Saudi wealth fund leaders

Associated Press Finance

10 months ago

PGA Tour reports 'progress' without details in meeting with Saudi wealth fund leaders

Here's Why Wabash National (NYSE:WNC) Has Caught The Eye Of Investors

Simply Wall St.

10 months ago

Here's Why Wabash National (NYSE:WNC) Has Caught The Eye Of Investors

Earnings Update: Here's Why Analysts Just Lifted Their Lands' End, Inc. (NASDAQ:LE) Price Target To US$17.67

Simply Wall St.

10 months ago

Earnings Update: Here's Why Analysts Just Lifted Their Lands' End, Inc. (NASDAQ:LE) Price Target To US$17.67

Shareholders in Bloom Energy (NYSE:BE) have lost 42%, as stock drops 9.1% this past week

Simply Wall St.

10 months ago

Shareholders in Bloom Energy (NYSE:BE) have lost 42%, as stock drops 9.1% this past week

We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth

Simply Wall St.

10 months ago

We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth

GuruFocus.com

a year ago

C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations

MT Newswires

a year ago

Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating

MT Newswires

a year ago

C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

GlobeNewswire

a year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

a year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)

Insider Monkey

a year ago

Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

a year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

GlobeNewswire

a year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Simply Wall St.

a year ago

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

a year ago

C4 Therapeutics Full Year 2023 Earnings: Misses Expectations

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a year ago

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates

C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates

GuruFocus.com

a year ago

C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

Zacks

a year ago

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zacks

a year ago

C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Global Water Resources Declares Monthly Dividend

GlobeNewswire

a year ago

Global Water Resources Declares Monthly Dividend

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

GuruFocus.com

a year ago

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Hawaiian Airlines ekes out Q4 revenue beat, earnings losses

Yahoo Finance Video

a year ago

Hawaiian Airlines ekes out Q4 revenue beat, earnings losses

Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group

Zacks

a year ago

Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group

GlobeNewswire

a year ago

F&M Bank Signs Atlanta Braves’ Kade Kern to Brand Partnership

With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors

NaaS Technology Included in the Investment Portfolio of Carbon Collective Climate Change Solutions ETF (CCSO.O)

PR Newswire

a year ago

NaaS Technology Included in the Investment Portfolio of Carbon Collective Climate Change Solutions ETF (CCSO.O)

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Zacks

a year ago

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

Farmers National Banc Corp. Reports Year-End Growth Amidst Economic Challenges

GuruFocus.com

a year ago

Farmers National Banc Corp. Reports Year-End Growth Amidst Economic Challenges

Vehicle Retailer Stocks Q3 Teardown: CarMax (NYSE:KMX) Vs The Rest

StockStory

a year ago

Vehicle Retailer Stocks Q3 Teardown: CarMax (NYSE:KMX) Vs The Rest

Great Southern Bancorp (GSBC) Q4 Earnings and Revenues Lag Estimates

Zacks

a year ago

Great Southern Bancorp (GSBC) Q4 Earnings and Revenues Lag Estimates

CrossFirst Bankshares (CFB) Q4 Earnings Surpass Estimates

Zacks

a year ago

CrossFirst Bankshares (CFB) Q4 Earnings Surpass Estimates

Should Value Investors Buy Financial Institutions (FISI) Stock?

Zacks

a year ago

Should Value Investors Buy Financial Institutions (FISI) Stock?

CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%

Simply Wall St.

a year ago

CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 16% this week, taking three-year losses to 89%

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

Business Wire

a year ago

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

Why Calavo Growers Stock Dropped Today

Motley Fool

a year ago

Why Calavo Growers Stock Dropped Today

Sales And Marketing Software Stocks Q3 Highlights: Sprinklr (NYSE:CXM)

StockStory

a year ago

Sales And Marketing Software Stocks Q3 Highlights: Sprinklr (NYSE:CXM)

Yext to Present at Upcoming Investor Conferences

Business Wire

a year ago

Yext to Present at Upcoming Investor Conferences

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

Business Wire

a year ago

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn

Zacks

a year ago

C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESSWIRE

a year ago

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

Landsea (LSEA) on Expansion Spree, To Acquire Antares Homes

Zacks

a year ago

Landsea (LSEA) on Expansion Spree, To Acquire Antares Homes

MOB WITH A PURPOSE: DENNY'S SELECTS DAD-RUN COMMUNITY IMPROVEMENT START-UP AS TRILLION-DOLLAR INCUBATOR CONTEST WINNER

GlobeNewswire

a year ago

MOB WITH A PURPOSE: DENNY'S SELECTS DAD-RUN COMMUNITY IMPROVEMENT START-UP AS TRILLION-DOLLAR INCUBATOR CONTEST WINNER

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick

Zacks

a year ago

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick

Share on Social Networks: